ArticleEuropean journal of nuclear medicine and molecular imaging2022
Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Transforming Gastrointestinal Diagnosis with Molecular Endoscopy: Challenges and Opportunities.International journal of molecular sciences · 2025Review
- Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett's Esophagus Using EMI-137 Fluorescence Imaging.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Improved ex vivo fluorescence imaging of human head and neck cancer using the peptide tracer TPP-IRDye800 targeting membrane-bound Hsp70 on tumor cells.British journal of cancer · 2024Article
- Membrane-bound Heat Shock Protein mHsp70 Is Required for Migration and Invasion of Brain Tumors.Cancer research communications · 2024Article
- PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- X-ray reflectivity study of the heat shock protein Hsp70 interaction with an artificial cell membrane model.Scientific reports · 2023Article
- Esophageal organoids: applications and future prospects.Journal of molecular medicine (Berlin, Germany) · 2023Review
- Application of near-infrared fluorescence imaging in theranostics of gastrointestinal tumors.Gastroenterology report · 2023Review
- Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.Diagnostics (Basel, Switzerland) · 2022Review
- Impact of the Tumor Microenvironment for Esophageal Tumor Development-An Opportunity for Prevention?Cancers · 2022Review
- CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus.EJNMMI research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeThe incidence of esophageal adenocarcinoma (EAC) has been increasing for decades without significant improvements in treatment. Barrett's esophagus (BE) is best established risk factor for EAC, but current surveillance with random biopsies cannot predict progression to cancer in most BE patients due to the low sensitivity and specificity of high-definition white light endoscopy.
methodsHere, we evaluated the membrane-bound highly specific Hsp70-specific contrast agent Tumor-Penetrating Peptide (Hsp70-TPP) in guided fluorescence molecular endoscopy biopsy.
resultsHsp70 was significantly overexpressed as determined by IHC in dysplasia and EAC compared with non-dysplastic BE in patient samples (n = 12) and in high-grade dysplastic lesions in a transgenic (L2-IL1b) mouse model of BE. In time-lapse microscopy, Hsp70-TPP was rapidly taken up and internalized by human BE dysplastic patient-derived organoids. Flexible fluorescence endoscopy of the BE mouse model allowed a specific detection of Hsp70-TPP-Cy5.5 that corresponded closely with the degree of dysplasia but not BE. Ex vivo application of Hsp70-TPP-Cy5.5 to freshly resected whole human EAC specimens revealed a high (> 4) tumor-to-background ratio and a specific detection of previously undetected tumor infiltrations.
conclusionIn summary, these findings suggest that Hsp70-targeted imaging using fluorescently labeled TPP peptide may improve tumor surveillance in BE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.